影响肝癌患者肝移植术后复发的血管因素研究进展

石鑫林; 王继洲; 姜洪池; 陆朝阳; 刘连新

doi:10.3969/j.issn.1674-7445.2019.06.017

影响肝癌患者肝移植术后复发的血管因素研究进展

doi: 10.3969/j.issn.1674-7445.2019.06.017

150001 哈尔滨医科大学附属第一医院普外科（石鑫林、姜洪池、陆朝阳、王继洲）；中国科技大学附属第一医院普外科（刘连新）

基金项目:

黑龙江省青年科学基金项目 QC2012C112

黑龙江省普通本科高等学校青年创新人才培养计划 UNPYSCT-2016199

详细信息

作者简介:
石鑫林，男，1994年生，硕士研究生，医师，研究方向为器官移植，Email：13176136706@163.com

通讯作者:
王继洲，男，1984年生，博士，副主任医师，研究方向为肝纤维化，Email：wangjizhouhmu@163.com

中图分类号: R617, R735.7
计量
- 文章访问数: 116
- HTML全文浏览量: 63
- PDF下载量: 10
- 被引次数: 0
出版历程
- 收稿日期: 2019-07-17
- 网络出版日期: 2021-01-19
- 刊出日期: 2019-11-15

Research progress of vascular factors affecting recurrence after liver transplantation in patients with hepatocellular carcinoma

摘要

摘要: 肝移植是治疗终末期肝病以及肝脏恶性肿瘤最有效的治疗手段，而肝癌患者行肝移植术后复发是临床优先考虑的问题。肿瘤新生血管的生成是肝癌术后复发的重要原因，近年来国内外在靶向抑制肿瘤血管生成方面取得了显著进展。本文对肝癌肝移植术后肿瘤促血管生成因素及抗血管治疗的研究进展进行综述。
- 肝移植 /
- 肝癌 /
- 复发转移 /
- 肿瘤血管生成因子 /
- 促血管生成素 /
- 血小板衍生因子 /
- 血管内皮生长因子 /
- 肝细胞生长因子 /
- 免疫抑制剂 /
- 特异性抗血管生成抑制剂

HTML全文

参考文献(25)

[1]	BARBHUIYA MA, MIRANDO AC, SIMONS BW, et al. Therapeutic potential of an anti-angiogenic multimodal biomimetic peptide in hepatocellular carcinoma[J]. Oncotarget, 2017, 8(60):101520-101534. DOI: 10.18632/oncotarget.21148.
[2]	FOLKMAN J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971, 285(21):1182-1186. doi: 10.1056/NEJM197111182852108
[3]	SHIMIZU A, ZANKOV DP, KUROKAWA-SEO M, et al. Vascular endothelial growth factor-a exerts diverse cellular effects via small g proteins, rho and rap[J]. Int J Mol Sci, 2018, 19(4). pii: E1203. DOI: 10.3390/ijms19041203.
[4]	ZHANG W, KIM R, QUINTINI C, et al. Prognostic role of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma undergoing liver transplantation[J]. Liver Transpl, 2015, 21(1):101-111. DOI: 10.1002/lt.24013.
[5]	ZHAN P, QIAN Q, YU LK. Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a Meta-analysis[J]. Hepatobiliary Surg Nutr, 2013, 2(4):209-215. DOI: 10.3978/j.issn.2304-3881.2013.06.07.
[6]	FAILLACI F, MARZI L, CRITELLI R, et al. Liver angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after hepatitis C virus direct-acting antivirals[J]. Hepatology, 2018, 68(3):1010-1024. DOI: 10.1002/hep.29911.
[7]	FIORENTINO M, ALTIMARI A, RAVAIOLI M, et al. Predictive value of biological markers for hepatocellular carcinoma patients treated with orthotopic liver transplantation[J]. Clin Cancer Res, 2004, 10(5):1789-1795. doi: 10.1158/1078-0432.CCR-1149-3
[8]	ATAIDE EC, PERALES SR, SILVA MG, et al. Immunoexpression of heat shock protein 70, glypican 3, glutamine synthetase, and beta-catenin in hepatocellular carcinoma after liver transplantation: association between positive glypican 3 and beta-catenin with the presence of larger nodules[J]. Transplant Proc, 2017, 49(4):858-862. DOI: 10.1016/j.transproceed.2017.01.048.
[9]	MAASS T, THIERINGER FR, MANN A, et al. Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis[J]. Int J Cancer, 2011, 128(6):1259-1268. DOI: 10.1002/ijc.25469.
[10]	WEI T, ZHANG LN, LV Y, et al. Overexpression of platelet-derived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma[J]. Oncotarget, 2014, 5(21):10307-10317. doi: 10.18632/oncotarget.2537
[11]	GOYAL L, MUZUMDAR MD, ZHU AX. Targeting the HGF/c-MET pathway in hepatocellular carcinoma[J]. Clin Cancer Res, 2013, 19(9):2310-2318. DOI: 10.1158/1078-0432.CCR-12-2791.
[12]	CAI H, SAIYIN H, LIU X, et al. Nogo-B promotes tumor angiogenesis and provides a potential therapeutic target in hepatocellular carcinoma[J]. Mol Oncol, 2018, 12(12):2042-2054. DOI: 10.1002/1878-0261.12358.
[13]	郭晓东, 孟繁平, 熊璐.HIF-1α的表达在肝移植后肝癌复发与转移中的意义[J].现代生物医学进展, 2011, 11(5):876-879. http://d.old.wanfangdata.com.cn/Periodical/swcx201105022 GUO XD, MENG FP, XIONG L. Clinical significance of HIF-1α expression in recurrence and metastasis of patients with hepatocellular carcinoma undergoing liver transplantation[J]. Prog Mod Biomed, 2011, 11(5):876-879. http://d.old.wanfangdata.com.cn/Periodical/swcx201105022
[14]	罗来邦, 杨华, 罗丽芳, 等.Vasohibin-2与肝癌肝移植术后复发转移及预后的关系[J].实用癌症杂志, 2017, 32(3):370-374. doi: 10.3969/j.issn.1001-5930.2017.03.007 DOI: 10.3969/j.issn.1001-5930.2017.03.007. LUO LB, YANG H, LUO LF, et al. Correlation between expression of vasohibin-2 and recurrence/metastasis and prognosis of HCC liver transplant[J]. Pract J Cancer, 2017, 32(3):370-374. DOI: 10.3969/j.issn.1001-5930.2017.03.007.
[15]	李慧, 汪根树, 郑俊, 等.Zwint高表达对肝癌细胞增殖和肝癌肝移植预后的影响[J].器官移植, 2018, 9(2):122-129. doi: 10.3969/j.issn.1674-7445.2018.02.006 DOI: 10.3969/j.issn.1674-7445.2018.02.006. LI H, WANG GS, ZHENG J, et al. Effect of high expression of Zwint on the proliferation of hepatoma cells and the prognosis of liver transplantation for hepatocellular carcinoma[J]. Organ Transplant, 2018, 9(2):122-129. DOI: 10.3969/j.issn.1674-7445.2018.02.006.
[16]	曹毅, 吕立志, 江艺, 等.CNTN-1和VEGF-C表达水平与肝癌肝移植术后复发转移及预后的关系[J].器官移植, 2017, 8(2):154-160. doi: 10.3969/j.issn.1674-7445.2017.02.012 DOI: 10.3969/j.issn.1674-7445.2017.02.012. CAO Y, LYU LZ, JIANG Y, et al. Relationship between CNTN-1 and VEGF-C expression levels and recurrence, metastasis and prognosis of hepatocellular carcinoma patients after liver transplantation [J]. Organ Transplant, 2017, 8(2):154-160. DOI: 10.3969/j.issn.1674-7445.2017.02.012.
[17]	BOIGE V, MALKA D, BOURREDJEM A, et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma[J]. Oncologist, 2012, 17(8):1063-1072. DOI: 10.1634/theoncologist.2011-0465.
[18]	QI HL, ZHUANG BJ, LI CS, et al. Peri-operative use of sorafenib in liver transplantation: a time-to-event Meta-analysis[J]. World J Gastroenterol, 2015, 21(5):1636-1640. DOI: 10.3748/wjg.v21.i5.1636.
[19]	JUNG DH, TAK E, HWANG S, et al. Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence[J]. Liver Transpl, 2018, 24(7):932-945. DOI: 10.1002/lt.25191.
[20]	QU Z, JIANG C, WU J, et al. Lenalidomide induces apoptosis and inhibits angiogenesis via caspase-3 and VEGF in hepatocellular carcinoma cells[J]. Mol Med Rep, 2016, 14(5):4781-4786. DOI: 10.3892/mmr.2016.5797.
[21]	RODRÍGUEZ-PERÁLVAREZ M, TSOCHATZIS E, NAVEAS MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma[J]. J Hepatol, 2013, 59(6):1193-1199. DOI: 10.1016/j.jhep.2013.07.012.
[22]	CHOLONGITAS E, MAMOU C, RODRÍGUEZ-CASTRO KI, et al. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review[J]. Transpl Int, 2014, 27(10):1039-1049. DOI: 10.1111/tri.12372.
[23]	LI C, WU X, ZHANG H, et al. A huaier polysaccharide restrains hepatocellular carcinoma growth and metastasis by suppression angiogenesis[J]. Int J Biol Macromol, 2015, 75:115-120. DOI: 10.1016/j.ijbiomac.2015.01.016.
[24]	LIN J, CHEN Y, WEI L, et al. Ursolic acid inhibits colorectal cancer angiogenesis through suppression of multiple signaling pathways[J]. Int J Oncol, 2013, 43(5):1666-1674. DOI: 10.3892/ijo.2013.2101.
[25]	SÁNCHEZ RAMÍREZ J, MORERA DÍAZ Y, BEQUET-ROMERO M, et al. Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants[J]. BMC Immunol, 2017, 18(1):39. DOI: 10.1186/s12865-017-0222-z.